(16S,17R)-3-甲氧基-13,16-二甲基-7,8,9,11,12,14,15,17-八氢-6H-环戊二烯并[a]菲-16,17-二醇 | 5108-94-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: (16S,17R)-3-甲氧基-13,16-二甲基-7,8,9,11,12,14,15,17-八氢-6H-环戊二烯并[a]菲-16,17-二醇
• 英文名称: 3-methoxy-16α-methylestra-1,3,5(10)-triene-16β,17β-diol
• 英文别名: 16β-hydroxy-16α-methyl-3-O-methylestradiol；16b-Hydroxy-16-methyl-3-methyl ether 17b-estradiol；3-methoxy-16-methyl-estra-1,3,5(10)-triene-16β,17β-diol；3-Methoxy-16-methyl-oestra-1,3,5(10)-trien-16β,17β-diol；16α-methyl-3-methoxy-1,3,5(10)-estratriene-16β,17β-diol；mytatrienediol；(8R,9S,13S,14S,16S,17R)-3-methoxy-13,16-dimethyl-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-16,17-diol
• CAS: 5108-94-1
• 化学式: C₂₀H₂₈O₃
• 分子量: 316.441
• InChiKey: OOVXZFCPCSVSEM-NADOGSGZSA-N

物化性质

• 熔点：
  179-181°
• 比旋光度：
  D20 +71° in dioxane
• 沸点：
  451.3±45.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (16S,17R)-3-甲氧基-13,16-二甲基-7,8,9,11,12,14,15,17-八氢-6H-环戊二烯并[a]菲-16,17-二醇 在 sodium periodate 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以80%的产率得到3-methoxy-16-methyl-16-oxo-16,17-secoestra-1,3,5(10)-trien-17-al
  参考文献：
  名称：

  Stereoselectivity in the epoxidation and cis-hydroxylation of 16-methylene-estra-1,3,5(10)-trienes

  摘要：

  Epoxidation of 3-methoxy-16-methylene-estra-1,3,5(10)-trien-17-one in the presence of alkaline hydrogen peroxide gives rise to (16R)- and (16S)-spiro[3-methoxy-17-oxoestra-1,3,5(10)-triene-16,2'-oxirane] in similar proportions. Epoxidation of the corresponding 16-methlene 17 beta-alcohol and 16-methylene-17 beta-acetate with m-chloroperbenzoic acid does not display any significant directing effects associated with allylic functionality, whereas Sharpless epoxidation of the 16-methylene 17 beta-alcohol is highly stereoselective, leading exclusively to the (16R) isomer. cis-Hydroxylation of the 16-methylene 17-ketone with osmium tetroxide/4-methylmorpholine-4-oxide proceeds stereoselectively to give mainly 16 alpha-hydroxy-16 beta-hydroxymethyl-3-methoxyestra-1,3,5(10)-trien-17-one. The isomeric addition products derived from these reactions are correlated by appropriate interconversions, and the assignments are corroborated by comparative reactivity of derived products.

  DOI：

  10.1016/0039-128x(94)90018-3
• 作为产物：
  描述：

  3-methoxy-16-methylene-estra-1,3,5(10)-trien-17-one 在 sodium hydroxide 、 lithium aluminium tetrahydride 、 双氧水 作用下， 以 四氢呋喃 、 叔丁醇 为溶剂， 反应 4.0h， 生成 (16S,17R)-3-甲氧基-13,16-二甲基-7,8,9,11,12,14,15,17-八氢-6H-环戊二烯并[a]菲-16,17-二醇
  参考文献：
  名称：

  Stereoselectivity in the epoxidation and cis-hydroxylation of 16-methylene-estra-1,3,5(10)-trienes

  摘要：

  Epoxidation of 3-methoxy-16-methylene-estra-1,3,5(10)-trien-17-one in the presence of alkaline hydrogen peroxide gives rise to (16R)- and (16S)-spiro[3-methoxy-17-oxoestra-1,3,5(10)-triene-16,2'-oxirane] in similar proportions. Epoxidation of the corresponding 16-methlene 17 beta-alcohol and 16-methylene-17 beta-acetate with m-chloroperbenzoic acid does not display any significant directing effects associated with allylic functionality, whereas Sharpless epoxidation of the 16-methylene 17 beta-alcohol is highly stereoselective, leading exclusively to the (16R) isomer. cis-Hydroxylation of the 16-methylene 17-ketone with osmium tetroxide/4-methylmorpholine-4-oxide proceeds stereoselectively to give mainly 16 alpha-hydroxy-16 beta-hydroxymethyl-3-methoxyestra-1,3,5(10)-trien-17-one. The isomeric addition products derived from these reactions are correlated by appropriate interconversions, and the assignments are corroborated by comparative reactivity of derived products.

  DOI：

  10.1016/0039-128x(94)90018-3

文献信息

• Oligonucleotides comprising a non-phosphate backbone linkage
  申请人：Manoharan Muthiah

  公开号：US20060287260A1

  公开（公告）日：2006-12-21

  One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.

  本发明的一个方面涉及在3'-位置用磷酰胺基团取代的核糖核苷。在某些实施例中，磷酰胺基团是烷基磷酰胺基团。本发明的另一个方面涉及包含至少一个非磷酸酯连接的双链寡核苷酸。代表性的非磷酸酯连接包括磷酸酯、羟胺、羟基肼基、酰胺和碳酸酯连接。在某些实施例中，非磷酸酯连接是磷酸酯连接。在某些实施例中，非磷酸酯连接仅出现在一条链中。在某些实施例中，非磷酸酯连接出现在两条链中。在某些实施例中，配体结合到包含双链寡核苷酸的寡核苷酸链中的一条链上。在某些实施例中，配体结合到包含双链寡核苷酸的寡核苷酸链中的两条链上。在某些实施例中，寡核苷酸链包含至少一个修饰的糖基团。本发明的另一个方面涉及包含至少一个非磷酸酯连接的单链寡核苷酸。代表性的非磷酸酯连接包括磷酸酯、羟胺、羟基肼基、酰胺和碳酸酯连接。在某些实施例中，非磷酸酯连接是磷酸酯连接。在某些实施例中，配体结合到寡核苷酸链上。在某些实施例中，寡核苷酸包含至少一个修饰的糖基团。
• Oligonucleotides comprising a C5-modified pyrimidine
  申请人：Manoharan Muthiah

  公开号：US20050288244A1

  公开（公告）日：2005-12-29

  One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand. In certain embodiments, a ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, both of the oligonucleotide strands of the double-stranded oligonucleotide independently comprise a bound ligand. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. In certain embodiments, a phosphate linkage in one or both of the strands of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5β-cholanic acid. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety. In certain embodiments, a phosphate linkage of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5β-cholanic acid. The ligand improves the pharmacokinetic properties of the oligonucleotide.

  本发明的一个方面涉及包含至少一个配体的双链寡核苷酸。在某些实施例中，配体仅结合到构成双链寡核苷酸的两个核苷酸链中的一个。在某些实施例中，双链寡核苷酸的两个核苷酸链都独立地包含一个结合的配体。在某些实施例中，核苷酸链包含至少一个修饰的糖基。在某些实施例中，核苷酸链的一个或两个链中的磷酸酯键已被磷硫酸酯或磷二硫酸酯键替代。在一个首选实施例中，配体是胆固醇或5β-胆烷酸。本发明的另一个方面涉及包含至少一个配体的单链寡核苷酸。在某些实施例中，核苷酸包含至少一个修饰的糖基。在某些实施例中，核苷酸的磷酸酯键已被磷硫酸酯或磷二硫酸酯键替代。在一个首选实施例中，配体是胆固醇或5β-胆烷酸。配体改善了寡核苷酸的药代动力学性能。
• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS
  申请人：Connor Eric

  公开号：US20140356316A1

  公开（公告）日：2014-12-04

  The present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like.

  本发明提供了交联胺聚合物，用于有效地结合和清除胆盐从胃肠道。这些胆酸结合聚合物或其药物组合物可以被用于治疗各种疾病，包括高胆固醇血症、糖尿病、瘙痒、肠易激综合征-腹泻（IBS-D）、胆酸吸收不良等。